T-cell receptor recognizing peptide–MHC class II complex (TCR–pMHC class II)

The T-cell receptor (TCR) recognizing peptide–MHC class II complexes is a central event in the adaptive immune response, where the TCR on CD4+ T-helper cells directly binds to antigenic peptides displayed by major histocompatibility complex (MHC) class II molecules on antigen-presenting cells[1][4][6]. MHC class II molecules present peptides, typically of extracellular origin, to TCRs, enabling detection and response to a vast array of pathogens and abnormal self-proteins, but also potentially enabling recognition of self and altered self, contributing to autoimmunity and anti-tumor responses[1][6]. The ensemble of TCR–MHC class II engagement, along with costimulatory molecules like CD4 and CD28, triggers T-cell activation, proliferation, cytokine release, and the shaping of adaptive immunity[1][5][6][7]. Drugs do not directly target this complex due to extreme diversity and tissue specificity, but indirect modulators exist (such as agents that affect costimulatory signals, or deplete T cells)[5]. An important technical note: “T-cell receptor via MHC class II” refers to a molecular interaction, not a single molecular entity, so it is not standard to list it as a canonical drug target; thus, is_incorrect: true. It is atypical to refer to “T-cell receptor via MHC class II” as a standalone canonical target because it describes a receptor–ligand interaction pair, not a unique molecule, thus this entry should be flagged as non-canonical for structured data purposes[4][5][6]. The T-cell receptor (TCR) and the MHC class II molecule (with its bound peptide) are both individually recognized targets, but their interaction is what is therapeutically relevant in certain contexts (particularly immunotherapy and autoimmunity), rather than either protein in isolation[1][4][5][6].

Other names

TCR–MHC IIT-cell receptor–MHC class II complexTCR–peptide–MHC class IIT-cell receptor interaction with MHC class II

Modulation of TCR–MHC class II interaction blocks T-cell activation; Interference with costimulatory pathways (such as CD28) to prevent immune synapse formation; Depletion of T cells (e.g., anti-CD3).